In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, CytomX Therapeutics Inc’s stock clocked out at $2.25, down -2.60% from its previous closing price of $2.31. In other words, the price has decreased by -$2.60 from its previous closing price. On the day, 2.54 million shares were traded. CTMX stock price reached its highest trading level at $2.44 during the session, while it also had its lowest trading level at $2.23.
Ratios:
To gain a deeper understanding of CTMX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.73. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.11.
Piper Sandler Upgraded its Neutral to Overweight on May 28, 2024, whereas the target price for the stock was revised from $2.25 to $3.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 16 ’25 when Ogden Christopher sold 10,614 shares for $2.69 per share. The transaction valued at 28,540 led to the insider holds 226,271 shares of the business.
Ogden Christopher sold 1,641 shares of CTMX for $4,841 on Jun 13 ’25. The Chief Financial Officer now owns 199,385 shares after completing the transaction at $2.95 per share. On Jun 16 ’25, another insider, BELVIN MARCIA, who serves as the SVP, Chief Scientific Officer of the company, sold 13,884 shares for $2.69 each. As a result, the insider received 37,334 and left with 272,252 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 354473984 and an Enterprise Value of 109660912. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.40 while its Price-to-Book (P/B) ratio in mrq is 7.24. Its current Enterprise Value per Revenue stands at 0.743 whereas that against EBITDA is 2.913.
Stock Price History:
The Beta on a monthly basis for CTMX is 2.08, which has changed by 0.6917293 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $3.10, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is 22.53%, while the 200-Day Moving Average is calculated to be 94.65%.
Shares Statistics:
It appears that CTMX traded 4.98M shares on average per day over the past three months and 2935750 shares per day over the past ten days. A total of 157.54M shares are outstanding, with a floating share count of 103.99M. Insiders hold about 33.99% of the company’s shares, while institutions hold 35.39% stake in the company. Shares short for CTMX as of 1749772800 were 20791019 with a Short Ratio of 4.18, compared to 1747267200 on 17729196. Therefore, it implies a Short% of Shares Outstanding of 20791019 and a Short% of Float of 13.71.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of CytomX Therapeutics Inc (CTMX).The consensus estimate for the next quarter is -$0.07, with high estimates of $0.02 and low estimates of -$0.12.
Analysts are recommending an EPS of between $0.23 and -$0.22 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.4, with 6.0 analysts recommending between -$0.01 and -$0.7.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $19.1M. It ranges from a high estimate of $30M to a low estimate of $4M. As of the current estimate, CytomX Therapeutics Inc’s year-ago sales were $25.11MFor the next quarter, 4 analysts are estimating revenue of $16.12M. There is a high estimate of $30M for the next quarter, whereas the lowest estimate is $4M.
A total of 5 analysts have provided revenue estimates for CTMX’s current fiscal year. The highest revenue estimate was $140.92M, while the lowest revenue estimate was $62.92M, resulting in an average revenue estimate of $98.75M. In the same quarter a year ago, actual revenue was $138.1MBased on 5 analysts’ estimates, the company’s revenue will be $64.97M in the next fiscal year. The high estimate is $120M and the low estimate is $4M.
